Cyanocobalamin-loaded dissolving microneedles diminish skin inflammation in vivo

Tools

Guillot, Antonio José and Martínez-Navarrete, Miquel and Giner, Rosa Maria and Recio, Maria Carmen and Santos, Helder A. and Cordeiro, Ana Sara and Melero, Ana (2024) Cyanocobalamin-loaded dissolving microneedles diminish skin inflammation in vivo. Journal of Controlled Release, 375. pp. 537-551. ISSN 0168-3659 (https://doi.org/10.1016/j.jconrel.2024.09.032)

[thumbnail of Guillot-etal-2024-Cyanocobalamin-loaded-dissolving-microneedles-diminish-skin-inflammation-in-vivo]
Preview
 Text. Filename: Guillot-etal-2024-Cyanocobalamin-loaded-dissolving-microneedles-diminish-skin-inflammation-in-vivo.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (10MB)| Preview

Abstract

Inflammatory diseases of the skin have a considerable high prevalence worldwide and negatively impact the patients' quality of life. First-line standard therapies for these conditions inherently entail important side effects when used long-term, particularly complicating the management of chronic cases. Therefore, there is a need to develop novel therapeutic strategies to offer reliable alternative treatments. Abnormally high reactive oxygen species (ROS) levels are characteristic of this kind of illnesses, and therefore a reasonable therapeutic goal. Cyanocobalamin, also known as Vitamin B12, possesses notable antioxidant and ROS-scavenging properties which could make it a possible therapeutic alternative. However, its considerable molecular weight restricts passive diffusion through the skin and forces the use of an advanced transdermal delivery system. Here, we present several prototypes of Cyanocobalamin-loaded Dissolving Microarray Patches (B12@DMAPs) with adequate mechanical properties to effectively penetrate the stratum corneum barrier, allowing drug deposition into the skin structure. Ex vivo penetration and permeability studies noted an effective drug presence within the dermal skin layers; in vitro compatibility studies in representative cell skin cell lines such as L929 fibroblasts and HaCaT keratinocytes ensured their safe use. The in vivo efficacy of the selected prototype was tested in a delayed-type hypersensitivity murine model that mimics an inflammatory skin process. Several findings such as a reduction of MPO-related photon emission in a bioluminescence study, protection against histological damage, and decrease of inflammatory cytokines levels point out the effectivity of B12@DMAPs to downregulate the skin inflammatory environment. Overall, B12@DMAPs offer a cost-effective translational alternative for improving patients' skin healthcare.

ORCID iDs

Guillot, Antonio José, Martínez-Navarrete, Miquel, Giner, Rosa Maria, Recio, Maria Carmen, Santos, Helder A., Cordeiro, Ana Sara ORCID logoORCID: https://orcid.org/0000-0003-4809-7916 and Melero, Ana;
CORE (COnnecting REpositories)